Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 4
2021 5
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.
Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof TWM, Bridoux J, Kerre T, De Beule N, De Becker A, De Bruyne E, Menu E, Vanderkerken K, Breckpot K, Devoogdt N, De Veirman K. Vandewalle N, et al. Among authors: de groof twm. Theranostics. 2024 Apr 15;14(7):2656-2674. doi: 10.7150/thno.91456. eCollection 2024. Theranostics. 2024. PMID: 38773967 Free PMC article.
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Hanssens H, Meeus F, De Vlaeminck Y, Lecocq Q, Puttemans J, Debie P, De Groof TWM, Goyvaerts C, De Veirman K, Breckpot K, Devoogdt N. Hanssens H, et al. Among authors: de groof twm. Front Immunol. 2024 Apr 19;15:1389018. doi: 10.3389/fimmu.2024.1389018. eCollection 2024. Front Immunol. 2024. PMID: 38720898 Free PMC article.
Current status and future expectations of nanobodies in oncology trials.
De Pauw T, De Mey L, Debacker JM, Raes G, Van Ginderachter JA, De Groof TWM, Devoogdt N. De Pauw T, et al. Among authors: de groof twm. Expert Opin Investig Drugs. 2023 Jul-Dec;32(8):705-721. doi: 10.1080/13543784.2023.2249814. Epub 2023 Aug 28. Expert Opin Investig Drugs. 2023. PMID: 37638538 Review.
A few good reasons to use nanobodies for cancer treatment.
Jumapili NA, Zivalj M, Barthelmess RM, Raes G, De Groof TWM, Devoogdt N, Stijlemans B, Vincke C, Van Ginderachter JA. Jumapili NA, et al. Among authors: de groof twm. Eur J Immunol. 2023 Sep;53(9):e2250024. doi: 10.1002/eji.202250024. Epub 2023 Jun 27. Eur J Immunol. 2023. PMID: 37366246 Review.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: de groof twm. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
20 results